With bucks from Pfiz­er added to their new round, Am­plyx steers a tricky course through PhII and a glob­al pan­dem­ic

5 years ago
Financing
R&D

Covid-19 roundup: Trump says he's been tak­ing hy­drox­y­chloro­quine for days; Mod­er­na rais­es $1.3B on the heels of ...

5 years ago
Coronavirus

GSK sub’s in­jectable out­per­forms Gilead in late-stage PrEP tri­al

5 years ago
R&D

Mar­tin Mack­ay’s rare dis­ease start­up gets $145 mil­lion as it en­ters the clin­ic

5 years ago
Financing
Startups

Years af­ter Keytru­da, Roche's Tecen­triq monother­a­py wins first-line NSCLC ap­proval. So does it mat­ter?

5 years ago
R&D
FDA+

FDA up­dates Covid-19 clin­i­cal tri­als guid­ance to ad­dress se­ri­ous ad­verse events

5 years ago
FDA+
Coronavirus

Roche’s James Sabry ze­roes in on a new path­way for pro­tein degra­da­tion — and he’s pay­ing $135M cash for a hot ...

5 years ago
Deals

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

5 years ago
Financing
China

SEC backs Sino­vac's case against ac­tivist in­vestor who tried to take over; Blue­bird pen­cils in $400M raise

5 years ago
News Briefing

Swe­den's Cal­lid­i­tas seeks $75M IPO haul to bring its oral steroid to pa­tients with an or­phan kid­ney dis­ease

5 years ago
Financing

J&J posts a sol­id round of pos­i­tive ear­ly da­ta for their BC­MA/CD3 bis­pe­cif­ic teclis­tam­ab, high­light­ing block­buster ...

5 years ago
R&D

As­traZeneca nabs break­through sta­tus, as $7B ADC races to block­buster sta­tus

5 years ago
R&D
FDA+

Oblit­er­at­ed by Alzheimer's fail­ure, Neu­rotrope re­lin­quish­es its Nas­daq spot in re­verse merg­er

5 years ago
Deals

Bob Langer-found­ed cell ther­a­py play­er loads up $65M to fund Roche-part­nered can­cer work while ex­pand­ing in­to ...

5 years ago
Financing
Cell/Gene Tx

Mod­er­na posts a promis­ing snap­shot of hu­man da­ta for a lead­ing Covid-19 vac­cine — and ral­ly makes Bob Langer a ...

5 years ago
R&D
Coronavirus

Covid-19 roundup: Kate Bing­ham to lead UK task­force; Fed­er­al judge to Shkre­li: You’re not go­ing to save the world, ...

5 years ago
Coronavirus

Clo­vis' Rubra­ca wins prostate can­cer ap­proval, but da­ta from ri­val Lyn­parza damp­en com­mer­cial ex­pec­ta­tions

5 years ago
R&D
FDA+

Mon­cef Slaoui piv­ots from Mod­er­na's board to the helm of Project Warp Speed. His task: Overnight suc­cess

5 years ago
People
Bioregnum

J&J jumps in­to gam­ma delta field with La­va col­lab­o­ra­tion; Myokar­dia guns for $605M raise

5 years ago
News Briefing

Look­ing for first-in-class glo­ry, Boehringer In­gel­heim ac­quires two pre­clin­i­cal can­cer drugs from Ver­sant-backed ...

5 years ago
Deals

Rare dis­ease drug­mak­er Ul­tragenyx builds case for its gene ther­a­py fran­chise with fresh tri­al up­dates

5 years ago
R&D
Cell/Gene Tx

Af­ter a PhI­II fail­ure, the FDA de­liv­ers Blue­print an ex­pect­ed CRL

5 years ago
R&D
FDA+

Sanofi scores a snap re­view for a rare dis­ease drug, an­oth­er win for the come­back play­ers in R&D

5 years ago
R&D
FDA+

Cher­ry Thomas joins Cari­bou as SVP of clin­i­cal de­vel­op­ment; Ar­tax locks in Joseph Lobac­ki as CEO

5 years ago
Peer Review
First page Previous page 826827828829830831832 Next page Last page
A service from the Financial Times